NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study
Journal of Alzheimer’s Disease · 2025-12 · 108 (3) · 1422-1435
DOI: 10.1177/13872877251386885 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 22.10.2025. Verfasst von Saily Sosa Pérez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Iván Portuondo, San Antonio de los Baños, Artemisa, Cuba. Hauptthemen laut MEDLINE: Alzheimer Disease, Erythropoietin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Center of Molecular Immunology, The Cuban Ministry of Public Health..
Themen: Demenz
Abstract (Originalsprache)
Background
NeuroEPO plus is a recombinant erythropoietin with a sialic acid content like that produced by astrocytes, lacking the hematopoietic activity of conventional erythropoietin.
Objective
To evaluate the efficacy and safety of treatment with neuroEPO plus.
Methods
It was a post-trial observational follow-up study with four groups, NE: subjects who continued treatment with neuroEPO plus after trial, PB-NE: subjects who received a placebo during the trial and then receive neuroEPO plus, NE-CTRL: subjects who received neuroEPO plus during the trial and then interrupted treatment and CTRL: subjects who were never treated. NeuroEPO plus was administrated three times a week nasally. The primary outcome was changed from baseline in the score on the11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog11) at 96 weeks. Secondary outcomes included Global Deterioration Scale, Montreal Cognitive Assessment, Neuropsychiatric Inventory, and Lawton Instrumental Activities of Daily Living Scale.
Results
The adjusted median change from baseline in the ADAS-Cog11 score at 96 weeks was −6.0 in NE group and 11.0 in the CTRL group (difference, 21.0; 95% confidence interval [CI], 14.6–27.4; p = 0.000), −1.0 in the PB-NE (difference, 15.4; 95% CI, 9.0–21.8; p = 0.000) and 4.0 in the NE-CTRL (difference, 8.3; 95% CI, 1.4–15.2; p = 0.011). The results for secondary outcomes showed statistically significant differences.
Conclusions
Subjects who continued or started treatment with neuroEPO plus stabilized or slowed down the progression of the disease. These results and the method of drug administration, make neuroEPO plus an attractive option to consider for Alzheimer's disease patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Iván Portuondo, San Antonio de los Baños, Artemisa, Cuba.
- Center of Molecular Immunology (CIM), Havana, Cuba.
ORCID-Profile: Patricia Lorenzo-Luaces, Lizet Sánchez Valdés, Tania Crombet Ramos, Kalet León Monzón, Teresita de Jesús Rodríguez Obaya, Leslie Pérez Ruiz
Förderung
- Center of Molecular Immunology
- The Cuban Ministry of Public Health.
Zitieren
APA
Sosa Pérez, S., Urrutia Amable, N., Viada González, C. E., Lorenzo-Luaces, P., Sánchez Valdés, L., Crombet Ramos, T., León Monzón, K., Rodríguez Obaya, T. J., & Pérez Ruiz, L. (2025). NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study. Journal of Alzheimer’s Disease, 108(3), 1422-1435. https://doi.org/10.1177/13872877251386885
Vancouver
Sosa Pérez S, Urrutia Amable N, Viada González CE, Lorenzo-Luaces P, Sánchez Valdés L, Crombet Ramos T, et al. NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study. Journal of Alzheimer’s Disease. 2025;108(3):1422-1435. doi:10.1177/13872877251386885
BibTeX
@article{SosaPrez2025,
author = {Sosa Pérez, Saily and Urrutia Amable, Nelky and Viada González, Carmen Elena and Lorenzo-Luaces, Patricia and Sánchez Valdés, Lizet and Crombet Ramos, Tania and León Monzón, Kalet and Rodríguez Obaya, Teresita de Jesús and Pérez Ruiz, Leslie},
title = {NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
volume = {108},
number = {3},
pages = {1422--1435},
doi = {10.1177/13872877251386885}
}
EUVIMED